Novel adenosine deaminase homolog

Abstract

This invention provides a novel isolated polynucleotide sequence, called ADARP1 (adenosine deaminase related protein 1), that displays significant homology to the adenosine deaminase (ADA) gene. Also provided is the amino acid sequence of the ADARP1 polypeptide encoded by the polynucleotide of the invention. The RNA for this novel gene is found in variety of tissues, with higher levels observed in the heart, testes, and skeletal muscle compared with others tested. Based on amino acid sequence homology, the ADARP1 protein will likely display the catalytic activity characteristic of ADA. This newly found ADARP1 gene and its encoded product may be useful in the treatment of immunodeficiencies, including severe combined immunodeficiency disease (SCID) and other ADA deficiencies, treatment of male reproductive disorders, testicular disorders and musclo-skeletal disorders.

1 - 58 . (canceled)  
     
     
         59 . An isolated antibody or fragment thereof that binds to a polypeptide selected from the group consisting of: 
 a.) the polypeptide comprising amino acids 1 to 267 of SEQ ID NO:2;    b.) the polypeptide comprising amino acids 2 to 267 of SEQ ID NO:2; and    c.) the ADARP1 polypeptide as encoded by the cDNA clone contained in ATCC Deposit No: PTA-2678.    
     
     
         60 . The isolated antibody or fragment thereof of  claim 59 , wherein said antibody is (a).  
     
     
         61 . The isolated antibody or fragment thereof of  claim 59 , wherein said antibody is (b).  
     
     
         62 . The isolated antibody or fragment thereof of  claim 59 , wherein said antibody is (c).  
     
     
         63 . The antibody according to  claim 59  which is polyclonal.  
     
     
         64 . The antibody according to  claim 59  which is monoclonal.  
     
     
         65 . The antibody according to  claim 59  which is chimeric.  
     
     
         66 . The antibody according to  claim 59  which is humanized.  
     
     
         67 . The antibody according to  claim 59  which is mammalian.  
     
     
         68 . The antibody according to  claim 59  which is human.  
     
     
         69 . A hybridoma cell which produces the antibody according to  claim 64 .  
     
     
         70 . The antibody of  claim 59 , wherein the fragment is selected from the group consisting of a) a Fab fragment; b) a F(ab′)2 fragment, and c) a Fv fragment.  
     
     
         71 . The antibody of  claim 59  which is labeled.  
     
     
         72 . The antibody of  claim 71 , wherein the label is selected from the group consisting of: a) an enzyme; b) a fluorescent label; and c) a radioisotope.  
     
     
         73 . The antibody of  claim 71 , which specifically binds to said polypeptide in an ELISA.  
     
     
         74 . The antibody of  claim 71 , which specifically binds to said polypeptide in a competitive-binding assay.  
     
     
         75 . The antibody of  claim 71 , which specifically binds to said polypeptide in a radioimmunoassay.  
     
     
         76 . The antibody of  claim 71 , which specifically binds to said polypeptide in a FACS.  
     
     
         77 . A kit for detecting a polypeptide comprising amino acids 2 to 267 of SEQ ID NO:2 comprising: 
 a) the isolated antibody of  claim 59;  and    b) at least one component to detect binding of the isolated antibody to said polypeptide sequence.    
     
     
         78 . An isolated antibody obtained from an animal that has been immunized with a polypeptide encoded by the cDNA contained in ATCC deposit No. PTA-2678, wherein said antibody binds to an antigenic epitope-bearing polypeptide fragment comprising at least 5 contiguous amino acids of said polypeptide.